|1.||Kinsella, Timothy J: 10 articles (08/2013 - 02/2003)|
|2.||Schupp, Jane E: 7 articles (08/2013 - 02/2003)|
|3.||van der Kogel, Albert J: 7 articles (05/2010 - 01/2005)|
|4.||Kaanders, Johannes H A M: 6 articles (05/2010 - 01/2005)|
|5.||De Clercq, Erik: 5 articles (01/2009 - 09/2002)|
|6.||Loparo, Kenneth A: 4 articles (08/2013 - 01/2006)|
|7.||Marres, Henri A M: 4 articles (04/2009 - 01/2005)|
|8.||Seo, Yuji: 4 articles (04/2006 - 11/2004)|
|9.||Yan, Tao: 4 articles (04/2006 - 11/2004)|
|10.||Radivoyevitch, Tomas: 4 articles (01/2006 - 02/2003)|
07/01/1993 - "Clearance of radioactivity was rapid in nonproliferative tissues; more than 80% of plasma radioactivity was cleared in 24 hr. Tumor-to-cortex radioactivity ratios ranged from 100/1 to 120/1 and 150/1 between 24, 48 and 96 hr after IUdR injection respectively. "
07/15/1995 - "The evidence we have obtained with EMT-6, the fifth rodent tumor we have studied with CldC, as well as the demonstrated and proposed reasons for its superior efficacy over 5-Iododeoxyuridine (and 5-Bromodeoxyuridine), drugs in current use, indicate that CldC will allow more aggressive treatment of human tumors with radiation than is now feasible."
08/01/1983 - "In vitro IFN-treated, [131I]5-iodo-2'-deoxyuridine-labeled tumor cells, when injected ip into normal syngeneic mice, were more rapidly eliminated than were untreated control cells. "
02/01/2000 - "However, greater image specificity and significance of the SUV and Tm:Br values would be obtained by achieving greater washout and clearance of the exchangeable fraction of residual (background) radioactivity in the tumors, i.e., by increased hydration and urinary clearance and possibly by imaging later than 24 h after [124I]IUdR administration."
05/01/2010 - "The current study demonstrated only a weak correlation between (18)F-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. "
01/01/1993 - "The efficacy of XXZ in the treatment of experimental Herpes Simplex Keratitis (HSK) in rabbits is higher than that of idoxuridine. "
02/01/1976 - "It was also effective in the treatment of idoxuridine-resistant herpetic keratitis. "
10/10/1981 - "In a double-blind, randomized trial 52 patients with superficial herpes simplex keratitis were treated with a new antiviral compound, acylclovir (ACV) 3% ointment, or with idoxuridine (IDU) 0.5% ointment. "
04/01/1975 - "In the present studies we treated experimental herpetic keratitis in rabbits with fluorescent light after using topical iododeoxyuridine (IDU) as a photosensitizing agent. "
01/01/2009 - "In 1959, 5-iodo-2'-deoxyuridine (IDU) was described, the first antiviral drug ever to be (and still) marketed (for the topical treatment of herpetic keratitis). "
12/01/1987 - "Measurement of the stratum corneum drug reservoir to predict the therapeutic efficacy of topical iododeoxyuridine for herpes simplex virus infection."
09/01/2002 - "Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice."
07/15/1994 - "Ocular problems were determined to be caused by infection with equine herpesvirus type 2 (EHV-2) and were successfully treated with ophthalmic medication containing idoxuridine. "
07/01/1989 - "[Iododeoxyuridine metabolism in the oral tissues and its alteration in infection by the herpes simplex virus]."
04/01/1989 - "In two patients with documented herpetic infections of the finger, the antiviral drug idoxuridine was applied to the lesions by cathodal iontophoresis. "
02/01/1979 - "The rabbit corneas treated with idoxuridine had a significantly more severe keratitis and yielded significantly greater numbers of S. "
01/01/1992 - "[Reversibility of IUdR resistance to sensitivity to an HSV1 strain in experimental keratitis in rabbits]."
01/01/1982 - "Idoxuridine treatment failures were found in 11 cases of herpetic superficial keratitis. "
10/01/1980 - "Idoxuridine for feline keratitis."
12/04/1963 - "THE TREATMENT OF VIRAL KERATITIS IN RABBITS WITH STOXIL (5-IODO-2-DESOXYURIDINE)]."
10/15/1994 - "We report the outcome of a Phase II study of a cohort of patients with high-grade glioma treated with accelerated hyperfractionated radiation and the radiation sensitizer, iododeoxyuridine (IdUrd). "
12/01/2014 - "First, we found the radioresistant rat 9L glioma cell line exhibited an SER10 due to the Auger effect of 1.35 at (35 keV, 18% IUdR) and an SER10 due to the radiosensitizing effect of 1.40 at (4 MV, 18% IUdR), both significantly less than values for previously reported cell lines. "
12/01/2014 - "Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy."
04/20/2001 - "Local polymeric delivery enhances IUdR radiosensitization of human malignant gliomas (MG). "
01/01/2000 - "To determine whether tumour incorporation of [125I]IUdR could be enhanced by protracted administration, we used a C6 cell line, growing in the brains of Wistar rats, as a glioma model and compared three methods of intracerebral delivery of [125I]IUdR. "
|6.||1- (2- deoxy- beta- ribofuranosyl)- 5- iodo- 2- pyrimidinone (IPdR)
|8.||DNA (Deoxyribonucleic Acid)
|10.||Antiviral Agents (Antivirals)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Laser Therapy (Surgery, Laser)